In another sign of biopharma’s growing belief in artificial intelligence (AI), Roche and its subsidiary Genentech have unveiled a major 10-year deal with Recursion Pharmaceuticals to use the technology to bring about "transformational” change in drug discovery.
Recursion will receive $150m upfront to provide its AI technology and collaborate with Roche and Genentech's R&D units to identify novel targets more rapidly and advance
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?